EXACT SCIENCES CORP Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 14 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-09-24: Reporting owner Hoof Torsten; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-08-19: Reporting owner Hoof Torsten; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-07-31: Reporting owner Carey Thomas D.; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-07-31: Reporting owner Elliott Jeffrey Thomas; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-09-24 | Hoof Torsten Officer (General Manager, International) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,401 4,399 owned after | $41.53 exercise price | 2020-09-28 | |
| 2020-08-19 | Hoof Torsten Officer (General Manager, International) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,516 3,029 owned after | $43.40 | 2020-08-21 | |
| 2020-07-31 | Carey Thomas D. Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,620 0 owned after | $9.24 exercise price | 2020-08-04 | |
| 2020-07-31 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,638 58,362 owned after | $21.68 exercise price | 2020-08-04 | |
| 2020-07-31 | LEVANGIE DANIEL J Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,608 0 owned after | $10.18 exercise price | 2020-08-04 | |
| 2020-07-31 | LEVANGIE DANIEL J Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,257 0 owned after | $8.52 exercise price | 2020-08-04 | |
| 2020-07-31 | Zanotti Katherine S Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,772 0 owned after | $8.52 exercise price | 2020-08-04 | |
| 2020-07-31 | Zanotti Katherine S Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,257 0 owned after | $8.52 exercise price | 2020-08-04 | |
| 2020-02-19 | Cole G Bradley Officer (General Manager - Diagnostics) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,934 0 owned after | $35.28 exercise price | 2020-02-21 | |
| 2020-02-19 | Cole G Bradley Officer (General Manager - Diagnostics) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,422 0 owned after | $35.91 exercise price | 2020-02-21 | |
| 2020-02-14 | Stenhouse Mark Officer (President, Cologuard) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,445 11,445 owned after | $98.18 exercise price | 2020-02-18 | |
| 2020-02-14 | ORVILLE JACOB A Officer (General Manager, New Ventures) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,581 6,581 owned after | $98.18 exercise price | 2020-02-18 | |
| 2020-02-14 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,875 12,875 owned after | $98.18 exercise price | 2020-02-18 | |
| 2020-02-14 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,916 100,916 owned after | $98.18 exercise price | 2020-02-18 |